• 1
    Clegg A, Bryant J, Nicholson T et al. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review. Int J Technol Assess Health Care 2002; 3: 497507.
  • 2
    Lefevre G, Sedek G, Jhee SS et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. Clin Pharmacol Ther 2008; 1: 106114.
  • 3
    Auriacombe S, Pere JJ, Loria-Kanza Y, Vellas B. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Curr Med Res Opin 2002; 3: 129138.
  • 4
    Winblad B, Cummings J, Andreasen N et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease—rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007; 5: 456467.
  • 5
    Winblad B, Kawata AK, Beusterien KM et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry 2007; 5: 485491.
  • 6
    Schmidt R, Alf C, Bancher C et al. Transdermal rivastigmine patch in outpatient services in Austria: a naturalistic study in 103 patients with Alzheimer dementia. Neuropsychiatr 2009; 1: 5863.
  • 7
    Grossberg GT, Olin JT, Somogyi M, Meng X. Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease. Int J Clin Pract 2011; 4: 465471.
  • 8
    Chiu PY, Dai DE, Hsu HP et al. Safety/tolerability and efficacy of rivastigmine in Taiwanese patients with Alzheimer's disease: a prospective post-marketing surveillance study. Clin Drug Investig 2009; 11: 729738.
  • 9
    Gauthier S, Juby A, Dalziel W, Rehel B, Schecter R. Effects of rivastigmine on common symptomatology of Alzheimer's disease (EXPLORE). Curr Med Res Opin 2010; 5: 11491160.
  • 10
    Lefevre G, Buche M, Sedek G et al. Similar rivastigmine pharmacokinetics and pharmacodynamics in Japanese and white healthy participants following the application of novel rivastigmine patch. J Clin Pharmacol 2009; 4: 430443.
  • 11
    Darreh-Shori T, Almkvist O, Guan ZZ et al. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology 2002; 4: 563572.
  • 12
    Cummings J, Winblad B. A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Rev Neurother 2007; 11: 14571463.
  • 13
    Grossberg G, Sadowsky C, Frostl H et al. Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension. Alzheimer Dis Assoc Disord 2009; 2: 158164.
  • 14
    Sadowsky CH, Farlow MR, Meng X, Olin JT. Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials. Int J Clin Pract 2010; 2: 188193.
  • 15
    Darreh-Shori T, Jelic V. Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia. Expert Opin Drug Saf 2010; 1: 167176.
  • 16
    Cummings JL, Farlow MR, Meng X, Tekin S, Olin JT. Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease. Clin Drug Investig 2010; 1: 4149.
  • 17
    Articus K, Baier M, Tracik F, Kuhn F, Preuss UW, Kurz A. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease. Int J Clin Pract 2011; 7: 790796.